291 related articles for article (PubMed ID: 27450735)
1. Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?
Samara P; Ioannou K; Tsitsilonis OE
Vitam Horm; 2016; 102():179-207. PubMed ID: 27450735
[TBL] [Abstract][Full Text] [Related]
2. Prothymosin Alpha: An Alarmin and More..
Samara P; Karachaliou CE; Ioannou K; Papaioannou NE; Voutsas IF; Zikos C; Pirmettis I; Papadopoulos M; Kalbacher H; Livaniou E; Tsitsilonis OE; Voelter W
Curr Med Chem; 2017; 24(17):1747-1760. PubMed ID: 28521686
[TBL] [Abstract][Full Text] [Related]
3. The immunologically active site of prothymosin alpha is located at the carboxy-terminus of the polypeptide. Evaluation of its in vitro effects in cancer patients.
Skopeliti M; Voutsas IF; Klimentzou P; Tsiatas ML; Beck A; Bamias A; Moraki M; Livaniou E; Neagu M; Voelter W; Tsitsilonis OE
Cancer Immunol Immunother; 2006 Oct; 55(10):1247-57. PubMed ID: 16453152
[TBL] [Abstract][Full Text] [Related]
4. Prothymosin alpha immunoactive carboxyl-terminal peptide TKKQKTDEDD stimulates lymphocyte reactions, induces dendritic cell maturation and adopts a beta-sheet conformation in a sequence-specific manner.
Skopeliti M; Iconomidou VA; Derhovanessian E; Pawelec G; Voelter W; Kalbacher H; Hamodrakas SJ; Tsitsilonis OE
Mol Immunol; 2009 Feb; 46(5):784-92. PubMed ID: 18976813
[TBL] [Abstract][Full Text] [Related]
5. Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy.
Ioannou K; Samara P; Livaniou E; Derhovanessian E; Tsitsilonis OE
Cancer Immunol Immunother; 2012 May; 61(5):599-614. PubMed ID: 22366887
[TBL] [Abstract][Full Text] [Related]
6. Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes.
Ioannou K; Derhovanessian E; Tsakiri E; Samara P; Kalbacher H; Voelter W; Trougakos IP; Pawelec G; Tsitsilonis OE
BMC Immunol; 2013 Sep; 14():43. PubMed ID: 24053720
[TBL] [Abstract][Full Text] [Related]
7. Intracellular and extracellular cytokine-like functions of prothymosin α: implications for the development of immunotherapies.
Mosoian A
Future Med Chem; 2011 Jul; 3(9):1199-208. PubMed ID: 21806381
[TBL] [Abstract][Full Text] [Related]
8. Specific in vitro binding of a new (99m)Tc-radiolabeled derivative of the C-terminal decapeptide of prothymosin alpha on human neutrophils.
Karachaliou CE; Liolios C; Triantis C; Zikos C; Samara P; Tsitsilonis OE; Kalbacher H; Voelter W; Papadopoulos M; Pirmettis I; Livaniou E
Int J Pharm; 2015; 486(1-2):1-12. PubMed ID: 25796124
[TBL] [Abstract][Full Text] [Related]
9. Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin α or its immunoactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice.
Voutsas IF; Pistamaltzian N; Tsiatas ML; Skopeliti M; Katsila T; Mavrothalassiti I; Spyrou S; Dimopoulos MA; Tsitsilonis OE; Bamias A
Eur J Cancer; 2013 May; 49(7):1706-14. PubMed ID: 23276721
[TBL] [Abstract][Full Text] [Related]
10. The C-terminal decapeptide of prothymosin α is responsible for its stimulatory effect on the functions of human neutrophils in vitro.
Samara P; Ioannou K; Neagu M; Arnogiannaki N; Ardavanis A; Voelter W; Tsitsilonis O
Int Immunopharmacol; 2013 Jan; 15(1):50-7. PubMed ID: 23201434
[TBL] [Abstract][Full Text] [Related]
11. Proteomic exploitation on prothymosin alpha-induced mononuclear cell activation.
Skopeliti M; Kratzer U; Altenberend F; Panayotou G; Kalbacher H; Stevanovic S; Voelter W; Tsitsilonis OE
Proteomics; 2007 Jun; 7(11):1814-24. PubMed ID: 17474146
[TBL] [Abstract][Full Text] [Related]
12. Immunogenic Cell Death, DAMPs and Prothymosin α as a Putative Anticancer Immune Response Biomarker.
Birmpilis AI; Paschalis A; Mourkakis A; Christodoulou P; Kostopoulos IV; Antimissari E; Terzoudi G; Georgakilas AG; Armpilia C; Papageorgis P; Kastritis E; Terpos E; Dimopoulos MA; Kalbacher H; Livaniou E; Christodoulou MI; Tsitsilonis OE
Cells; 2022 Apr; 11(9):. PubMed ID: 35563721
[TBL] [Abstract][Full Text] [Related]
13. Development of an ELISA for the quantification of the C-terminal decapeptide prothymosin α(100-109) in sera of mice infected with bacteria.
Samara P; Kalbacher H; Ioannou K; Radu DL; Livaniou E; Promponas VJ; Voelter W; Tsitsilonis O
J Immunol Methods; 2013 Sep; 395(1-2):54-62. PubMed ID: 23831611
[TBL] [Abstract][Full Text] [Related]
14. A fragment of the alarmin prothymosin α as a novel biomarker in murine models of bacteria-induced sepsis.
Samara P; Miriagou V; Zachariadis M; Mavrofrydi O; Promponas VJ; Dedos SG; Papazafiri P; Kalbacher H; Voelter W; Tsitsilonis O
Oncotarget; 2017 Jul; 8(30):48635-48649. PubMed ID: 28611290
[TBL] [Abstract][Full Text] [Related]
15. Novel neuroprotective action of prothymosin α-derived peptide against retinal and brain ischemic damages.
Halder SK; Matsunaga H; Yamaguchi H; Ueda H
J Neurochem; 2013 Jun; 125(5):713-23. PubMed ID: 23278181
[TBL] [Abstract][Full Text] [Related]
16. The thymosins. Prothymosin alpha, parathymosin, and beta-thymosins: structure and function.
Hannappel E; Huff T
Vitam Horm; 2003; 66():257-96. PubMed ID: 12852257
[TBL] [Abstract][Full Text] [Related]
17. In Vitro Immunodetection of Prothymosin Alpha in Normal and Pathological Conditions.
Karachaliou CE; Kalbacher H; Voelter W; Tsitsilonis OE; Livaniou E
Curr Med Chem; 2020; 27(29):4840-4854. PubMed ID: 31389310
[TBL] [Abstract][Full Text] [Related]
18. Prothymosin α and its C-Terminal Immunoreactive Decapeptide Show No Evidence of Acute Toxicity: A Preliminary
Birmpilis AI; Vitsos P; Kostopoulos IV; Williams L; Ioannou K; Samara P; Karachaliou CE; Voutsas IF; Alyfanti E; Angelis N; Gavalas NG; Gkraikou T; Kappa N; Klagkou E; Klimentzou P; Nikou S; Papaioannou NE; Skopeliti M; Toukli D; Dimopoulos MA; Bamias A; Livaniou E; Kalbacher H; Tsitsilonis OE; Voelter W
Curr Med Chem; 2022; 29(42):6463-6478. PubMed ID: 34789121
[TBL] [Abstract][Full Text] [Related]
19. Prothymosin-α Variants Elicit Anti-HIV-1 Response via TLR4 Dependent and Independent Pathways.
Gusella GL; Teixeira A; Aberg J; Uversky VN; Mosoian A
PLoS One; 2016; 11(6):e0156486. PubMed ID: 27310139
[TBL] [Abstract][Full Text] [Related]
20. Prothymosin-alpha inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction.
Mosoian A; Teixeira A; Burns CS; Sander LE; Gusella GL; He C; Blander JM; Klotman P; Klotman ME
Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10178-83. PubMed ID: 20479248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
